T1	AdverseReaction 54 80	Hypersensitivity reactions
T2	AdverseReaction 98 102	rash
T3	AdverseReaction 143 160	organ dysfunction
T4	AdverseReaction 172 184	liver injury
T5	AdverseReaction 515 538	transaminase elevations
T6	AdverseReaction 783 797;811 822	Redistribution of body fat
T7	AdverseReaction 798 822	accumulation of body fat
T8	AdverseReaction 827 857	immune reconstitution syndrome
T9	DrugClass 902 936	combination antiretroviral therapy
T10	AdverseReaction 1004 1020	Hypersensitivity
T11	AdverseReaction 1076 1080	rash
T12	AdverseReaction 1121 1138	organ dysfunction
T13	AdverseReaction 1150 1162	liver injury
T14	AdverseReaction 2216 2239	transaminase elevations
T15	AdverseReaction 2311 2338	elevations in transaminases
T16	AdverseReaction 2360 2390	immune reconstitution syndrome
T17	AdverseReaction 2394 2418	hepatitis B reactivation
T18	AdverseReaction 2733 2747;2761 2772	Redistribution of body fat
T19	AdverseReaction 2748 2772	accumulation of body fat
T20	AdverseReaction 2784 2799	central obesity
T21	AdverseReaction 2801 2830	dorsocervical fat enlargement
T22	AdverseReaction 2832 2844	buffalo hump
T23	AdverseReaction 2764 2772;2847 2865	body fat peripheral wasting
T24	AdverseReaction 2867 2881	facial wasting
T25	AdverseReaction 2883 2901	breast enlargement
T26	AdverseReaction 2908 2929	cushingoid appearance
T27	DrugClass 2972 2994	antiretroviral therapy
T28	AdverseReaction 3171 3201	Immune reconstitution syndrome
T29	AdverseReaction 3419 3440	inflammatory response
T30	AdverseReaction 3456 3489	residual opportunistic infections
T31	AdverseReaction 3499 3529	Mycobacterium avium  infection
T32	AdverseReaction 3531 3546	cytomegalovirus
T33	AdverseReaction 3548 3581	Pneumocystis jirovecii  pneumonia
T34	AdverseReaction 3583 3586	PCP
T35	AdverseReaction 3592 3604	tuberculosis
T36	AdverseReaction 3697 3712	Graves' disease
T37	AdverseReaction 3667 3687	Autoimmune disorders
T38	AdverseReaction 3714 3726	polymyositis
T39	AdverseReaction 3732 3755	Guillain-Barre syndrome
T41	Factor 478 482	risk
T42	Factor 2179 2183	risk
T43	Factor 3404 3407	may
E1	AdverseReaction:T1
E2	AdverseReaction:T2
E3	AdverseReaction:T3
E4	AdverseReaction:T4
E5	AdverseReaction:T5 Hypothetical:E41
E6	AdverseReaction:T6 Hypothetical:E9
E7	AdverseReaction:T7 Hypothetical:E9
E8	AdverseReaction:T8 Hypothetical:E9
E9	DrugClass:T9
E10	AdverseReaction:T10
E11	AdverseReaction:T11
E12	AdverseReaction:T12
E13	AdverseReaction:T13
E14	AdverseReaction:T14 Hypothetical:E42
E15	AdverseReaction:T15
E16	AdverseReaction:T16
E17	AdverseReaction:T17
E18	AdverseReaction:T18 Hypothetical:E27
E19	AdverseReaction:T19 Hypothetical:E27
E20	AdverseReaction:T20 Hypothetical:E27
E21	AdverseReaction:T21 Hypothetical:E27
E22	AdverseReaction:T22 Hypothetical:E27
E23	AdverseReaction:T23 Hypothetical:E27
E24	AdverseReaction:T24 Hypothetical:E27
E25	AdverseReaction:T25 Hypothetical:E27
E26	AdverseReaction:T26 Hypothetical:E27
E27	DrugClass:T27
E28	AdverseReaction:T28
E29	AdverseReaction:T29 Hypothetical:E43
E30	AdverseReaction:T30 Hypothetical:E43
E31	AdverseReaction:T31 Hypothetical:E43
E32	AdverseReaction:T32 Hypothetical:E43
E33	AdverseReaction:T33 Hypothetical:E43
E34	AdverseReaction:T34 Hypothetical:E43
E35	AdverseReaction:T35 Hypothetical:E43
E36	AdverseReaction:T36
E37	AdverseReaction:T37
E38	AdverseReaction:T38
E39	AdverseReaction:T39
E41	Factor:T41
E42	Factor:T42
E43	Factor:T43
A1	CUI E1 C0020517
A2	UMLS-Preferred-Name E1 Hypersensitivity
A3	MEDDRA-PT E1 Hypersensitivity
A4	MEDDRA-PT-ID E1 10020751
A5	LLT E1 Hypersensitivity reaction
A6	LLT-ID E1 10020756
A7	CUI E2 C0015230
A8	UMLS-Preferred-Name E2 Exanthema
A9	MEDDRA-PT E2 Rash
A10	MEDDRA-PT-ID E2 10037844
A11	CUI E3 C0349410
A12	UMLS-Preferred-Name E3 Single organ dysfunction
A13	MEDDRA-PT E3 Organ failure
A14	MEDDRA-PT-ID E3 10053159
A15	CUI E4 C0160390
A16	UMLS-Preferred-Name E4 Injury of liver
A17	MEDDRA-PT E4 Liver injury
A18	MEDDRA-PT-ID E4 10067125
A19	CUI E5 C0438717
A20	UMLS-Preferred-Name E5 Transaminases increased
A21	MEDDRA-PT E5 Transaminases increased
A22	MEDDRA-PT-ID E5 10054889
A23	CUI E6 C0856151
A24	UMLS-Preferred-Name E6 Fat redistribution
A25	MEDDRA-PT E6 Fat redistribution
A26	MEDDRA-PT-ID E6 10048474
A27	CUI E7 C1096393
A28	UMLS-Preferred-Name E7 Body fat disorder
A29	MEDDRA-PT E7 Body fat disorder
A30	MEDDRA-PT-ID E7 10055164
A31	CUI E8 C1096197
A32	UMLS-Preferred-Name E8 Immune reconstitution syndrome
A33	MEDDRA-PT E8 Immune reconstitution inflammatory syndrome
A34	MEDDRA-PT-ID E8 10065042
A35	LLT E8 Immune reconstitution syndrome
A36	LLT-ID E8 10054014
A37	CUI E10 C0020517
A38	UMLS-Preferred-Name E10 Hypersensitivity
A39	MEDDRA-PT E10 Hypersensitivity
A40	MEDDRA-PT-ID E10 10020751
A41	CUI E11 C0015230
A42	UMLS-Preferred-Name E11 Exanthema
A43	MEDDRA-PT E11 Rash
A44	MEDDRA-PT-ID E11 10037844
A45	CUI E12 C0349410
A46	UMLS-Preferred-Name E12 Single organ dysfunction
A47	MEDDRA-PT E12 Organ failure
A48	MEDDRA-PT-ID E12 10053159
A49	CUI E13 C0160390
A50	UMLS-Preferred-Name E13 Injury of liver
A51	MEDDRA-PT E13 Liver injury
A52	MEDDRA-PT-ID E13 10067125
A53	CUI E14 C0438717
A54	UMLS-Preferred-Name E14 Transaminases increased
A55	MEDDRA-PT E14 Transaminases increased
A56	MEDDRA-PT-ID E14 10054889
A57	CUI E15 C0438717
A58	UMLS-Preferred-Name E15 Transaminases increased
A59	MEDDRA-PT E15 Transaminases increased
A60	MEDDRA-PT-ID E15 10054889
A61	CUI E16 C1096197
A62	UMLS-Preferred-Name E16 Immune reconstitution syndrome
A63	MEDDRA-PT E16 Immune reconstitution inflammatory syndrome
A64	MEDDRA-PT-ID E16 10065042
A65	LLT E16 Immune reconstitution syndrome
A66	LLT-ID E16 10054014
A67	CUI E17 C1142420
A68	UMLS-Preferred-Name E17 Hepatitis B reactivation
A69	MEDDRA-PT E17 Hepatitis B
A70	MEDDRA-PT-ID E17 10019731
A71	LLT E17 Hepatitis B reactivation
A72	LLT-ID E17 10058827
A73	CUI E18 C0856151
A74	UMLS-Preferred-Name E18 Fat redistribution
A75	MEDDRA-PT E18 Fat redistribution
A76	MEDDRA-PT-ID E18 10048474
A77	CUI E19 C1096393
A78	UMLS-Preferred-Name E19 Body fat disorder
A79	MEDDRA-PT E19 Body fat disorder
A80	MEDDRA-PT-ID E19 10055164
A81	CUI E20 C0311277
A82	UMLS-Preferred-Name E20 Obesity, Abdominal
A83	MEDDRA-PT E20 Central obesity
A84	MEDDRA-PT-ID E20 10065941
A85	CUI E21 C0520573
A86	UMLS-Preferred-Name E21 Buffalo hump
A87	MEDDRA-PT E21 Lipohypertrophy
A88	MEDDRA-PT-ID E21 10062315
A89	LLT E21 Buffalo hump
A90	LLT-ID E21 10006539
A91	CUI E22 C0520573
A92	UMLS-Preferred-Name E22 Buffalo hump
A93	MEDDRA-PT E22 Lipohypertrophy
A94	MEDDRA-PT-ID E22 10062315
A95	LLT E22 Buffalo hump
A96	LLT-ID E22 10006539
A97	CUI E23 C0333650
A98	UMLS-Preferred-Name E23 Adipose Tissue Atrophy
A99	MEDDRA-PT E23 Lipoatrophy
A100	MEDDRA-PT-ID E23 10024604
A101	LLT E23 Fat atrophy NOS
A102	LLT-ID E23 10016242
A103	CUI E24 C1112303
A104	UMLS-Preferred-Name E24 Facial wasting
A105	MEDDRA-PT E24 Facial wasting
A106	MEDDRA-PT-ID E24 10056866
A107	CUI E25 C2225524
A108	UMLS-Preferred-Name E25 Macromastia
A109	MEDDRA-PT E25 Breast enlargement
A110	MEDDRA-PT-ID E25 10006242
A111	CUI E26 C0742929
A112	UMLS-Preferred-Name E26 CUSHINGOID APPEARANCE
A113	MEDDRA-PT E26 Cushingoid
A114	MEDDRA-PT-ID E26 10011655
A115	LLT E26 Cushingoid facies
A116	LLT-ID E26 10011656
A117	CUI E28 C1096197
A118	UMLS-Preferred-Name E28 Immune reconstitution syndrome
A119	MEDDRA-PT E28 Immune reconstitution inflammatory syndrome
A120	MEDDRA-PT-ID E28 10065042
A121	LLT E28 Immune reconstitution syndrome
A122	LLT-ID E28 10054014
A123	CUI E29 C1155266
A124	UMLS-Preferred-Name E29 inflammatory response
A125	MEDDRA-PT E29 Inflammation
A126	MEDDRA-PT-ID E29 10061218
A127	LLT E29 Inflammatory reaction
A128	LLT-ID E29 10021995
A129	CUI E30 C0029118
A130	UMLS-Preferred-Name E30 Opportunistic Infections
A131	MEDDRA-PT E30 Opportunistic infection
A132	MEDDRA-PT-ID E30 10030901
A133	CUI E31 C1411980
A134	UMLS-Preferred-Name E31 Mycobacterium avium infection
A135	MEDDRA-PT E31 Mycobacterium avium complex infection
A136	MEDDRA-PT-ID E31 10058806
A137	LLT E31 Infection mycobacterium avium
A138	LLT-ID E31 10021840
A139	CUI E32 C0010823
A140	UMLS-Preferred-Name E32 Cytomegalovirus Infections
A141	MEDDRA-PT E32 Cytomegalovirus infection
A142	MEDDRA-PT-ID E32 10011831
A143	CUI E33 C1535939
A144	UMLS-Preferred-Name E33 Pneumocystis jiroveci pneumonia
A145	MEDDRA-PT E33 Pneumocystis jirovecii pneumonia
A146	MEDDRA-PT-ID E33 10073755
A147	CUI E34 C1535939
A148	UMLS-Preferred-Name E34 Pneumocystis jiroveci pneumonia
A149	MEDDRA-PT E34 Pneumocystis jirovecii pneumonia
A150	MEDDRA-PT-ID E34 10073755
A151	CUI E35 C0041296
A152	UMLS-Preferred-Name E35 Tuberculosis
A153	MEDDRA-PT E35 Tuberculosis
A154	MEDDRA-PT-ID E35 10044755
A155	CUI E36 C0018213
A156	UMLS-Preferred-Name E36 Graves Disease
A157	MEDDRA-PT E36 Basedow's disease
A158	MEDDRA-PT-ID E36 10004161
A159	LLT E36 Graves' disease
A160	LLT-ID E36 10018706
A161	CUI E37 C0004364
A162	UMLS-Preferred-Name E37 Autoimmune Diseases
A163	MEDDRA-PT E37 Autoimmune disorder
A164	MEDDRA-PT-ID E37 10061664
A165	CUI E38 C0085655
A166	UMLS-Preferred-Name E38 Polymyositis
A167	MEDDRA-PT E38 Polymyositis
A168	MEDDRA-PT-ID E38 10036102
A169	CUI E39 C0018378
A170	UMLS-Preferred-Name E39 Guillain-Barre Syndrome
A171	MEDDRA-PT E39 Guillain-Barre syndrome
A172	MEDDRA-PT-ID E39 10018767
